Home lifeDomestic services apparel Entertainment News Player community More

Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area

OSAKA,Japan and MONTREAL,Dec. 6,2024 -- Ono Pharmaceutical Co.,Ltd. (Headquarters: Osaka,Japan; President:ToichiTakino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal,Quebec,Canada; CEO:Clarissa Desjardins; "Congruence") to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform,Revenir™.

Under the terms of the agreement,Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called,Revenir™. Ono will obtain an exclusive option right to develop,manufacture and commercialize the identified small molecule correctors worldwide. Congruence will be eligible to receive an upfront payment,research expenses,milestone payments based on research and development progress and sales,as well as tiered royalties based on net sales.

"We believe that this collaboration with Congruence may help generating novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology,leading to our development pipeline,"said Seishi Katsumata,Corporate Officer / Executive Director,Discovery & Research of Ono. "We will be committed to delivering innovative new drugs to cancer patients as soon as possible."

"Congruence is thrilled to partner with Ono,which has established itself as a global leader in drug development,particularly in the oncology space. We believe that our Revenir™ platform and capabilities in protein dynamics will accelerate the discovery of novel therapies for compelling targets of interest to both companies," said Sharath Hegde PhD,Chief Scientific Officer of Congruence.

About Revenir™ Drug Discovery Platform

Revenir™,Congruence's proprietary computational drug discovery platform,captures the dynamic biophysical changes caused by mutations in proteins,offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers,Revenir™ predicts small molecule induced correction of the underlying defect.

About Congruence Therapeutics

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Congruence's proprietary scalable platform,Revenir™,captures the biophysical features of proteins across their conformational ensembles,in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

For more information,please visit www.congruencetx.com.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

Federal Reserve Data Released: Industrial Output Continues to Decline

State Grid Bortala Power Supply Company: Achieving the Application of Feeder Automation

China Matters' Feature: Beidahuang: Green Development on Black Soil

Hong Kong Screen Legend Chow Yun Fat Hosts Charity Photography Exhibition "Hong Kong‧Morning" at Harbour City, Showcasing 30 Stunning City Photographs

GEEKOM's high-performance mini PCs will shine at CES2025

Potech Group Expands Global Presence with New Entity Launch in Australia

©copyright2009-2020New York Fashion News    Contact Us  SiteMap